The appetite-suppressing effects mediated through central nervous system pathways may also diminish, potentially leading to increased hunger and food intake
TRIUMPH-1 (NCT05929066) will look at the efficacy and safety of retatrutide in people with overweight/obesity without T2D and will include subsets of participants with knee osteoarthritis (OA) or OSA
Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank)
[5] Smits MM, Van Raalte DH